Gilead Oncology Triple Negative Prognosis | GileadPro

This website is intended for healthcare professionals only

Triple-negative breast cancers have a worse prognosis than other breast cancer subtypes, primarily because they grow faster and have a higher likelihood of developing distant metastases.1,2 Patients are also more often diagnosed in advanced stages of the disease compared with patients with other breast cancer subtypes.3

Relapse
The risk of early relapse following (neo)adjuvant chemotherapy, particularly within the first 2 years of diagnosis, is higher in patients with triple-negative breast cancer compared with hormone receptor-positive (HR+) breast cancer.2


Recurrence
Women with triple-negative breast cancer have a significantly higher risk of distant recurrence in their first five years of diagnosis compared with other breast cancer types.*4

*Hazard ratio: 1.5 (95% confidence interval: 1.1-2.0 (p<0.02), according to a Canadian database review of 1,601 women diagnosed with breast cancer.4


Metastases
Triple-negative breast cancer metastases occur more frequently in visceral organs including the lungs, liver, and central nervous system, which confers a poor disease prognosis.5-7


Metastatic survival
The five-year survival rate for metastatic triple-negative breast cancer survival is just 12%, compared with 91% and 65% for localised and regional disease, respectively.8

Median overall survival (OS) for patients with metastatic triple-negative breast cancer is approximately 14.8 months (95% confidence interval [CI]: 14.1-15.5). This is significantly lower (p<0.0001) than the median overall survival for both HR+/HER2- patients (43.3 months, 95% CI: 42.5-44.5) and HER2+ patients (50.1 months; 95% CI: 47.6-53.1).9


Triple-negative breast cancer outcomes


Dr Mark Harries, Consultant Medical Oncologist, Guy’s and St Thomas’ Hospitals Foundation Trust, compares triple-negative breast cancer outcomes with other breast cancer subtypes in this short video.

Topics covered include overall survival and 5-year relative survival at different disease stages.

He also shares results from a retrospective review conducted at the Royal Marsden Hospital, London, which shows how outcomes in metastatic triple-negative breast cancer change as lines of therapy increase.

(03:22 minutes)

References:

  1. Fangyuan, S, et al. Oncotarget. 2017;8(42):73329-73344.
  2. Sharma P. Oncologist. 2016;21(9):1050-1062.
  3. Bauer KR, et al. Cancer. 2007;109(9):1721-1728.
  4. Dent R, et al. Clin Cancer Res. 2007;13(15 Pt 1):4429-4434.
  5. Foulkes WD, et al. N Engl J Med. 2010;363(20):1938-1948.
  6. Sharma P. Oncologist. 2016;21(9):1050-1062.
  7. Lee A, Djamgoz MBA. Cancer Treat Rev. 2018;62:110-22.
  8. American Cancer Society. Triple-negative Breast Cancer. Available at: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html. Accessed: January 2024.
  9. Deluche E, et al. Eur J Canc. 2020; 60-67.

Related content

getty-images-1327475879

GMed Grand Rounds

A series of monthly, CPD-accredited case-based webinars delivered by respected oncology healthcare professionals.
Read more
getty-images-1385463753

Health Inequalities symposium video

Watch four multidisciplinary experts share their insights into cancer health inequalities, explaining the evidence and underlying causes behind them.
Read more
getty-images-1327624070

TNBC Support

TNBC Support is a website designed to support triple-negative breast cancer patients and their carers in the UK.

TNBC Support has been developed and funded by Gilead Sciences Ltd.
Read more

January 2024 UK-UNB-3381

Adverse events should be reported

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.